Omics-OS receives CHF 40,000 from Venture Kick to build the operating system for biology
23.06.2026
Omics-OS receives CHF 40,000 from Venture Kick to advance its agentic data platform for biotech research. By making multi-omics data accessible, harmonized, and actionable for both scientists and AI agents, the platform helps research teams generate reproducible analyses and partner-ready data packages faster and more efficiently.
 OmicsOS CEO Kevin Yar
|
 |
What was the first real signal that your solution worked outside the lab or pitch deck, and what did that moment change for you?
The first real signal came from a Swiss biotech consultancy that needed to deliver a harmonized multi-omics data package to a pharma partner under tight deadlines. Their team estimated six to eight weeks of manual work. Using Omics-OS, we delivered the same result in less than a month, and they paid for it.
That project confirmed something important for us: the biggest bottleneck isn’t data analysis itself, it’s finding, cleaning, and harmonizing data. After that, we stopped describing ourselves as an AI bioinformatics platform and started positioning Omics-OS as an agentic data access layer for biotech R&D.
Can you briefly describe your project and where it stood when you entered Venture Kick?
Omics-OS makes biological research data accessible, harmonized, and actionable for both scientists and AI agents. We think of it as an operating system for biology.
The platform combines an open-source multi-agent engine for bioinformatics workflows with a managed cloud workspace that enables reproducible analyses and partner-ready data packages without coding.
When we entered Venture Kick, we already had a production-grade platform and our first paying customer. What we lacked was a clear commercial focus, a repeatable sales process, and the resources to start building a team.
How has the direction of your product/service/product strategy changed since working with the Venture Kick Team?
Before Venture Kick, we were trying to sell the entire vision at once. The program pushed us to focus on a specific, urgent customer problem.
Instead of leading with the platform, we now focus on helping biotech teams quickly generate harmonized, auditable data packages when facing partnership, diligence, or research deadlines. That shift influenced our pricing, messaging, outreach, and product priorities. The vision remains the same, but the path to getting there is much clearer.
How will the Stage 2 funding help you advance your project concretely?
Stage 2 funding will support two priorities: growing the team and advancing our fundraising efforts.
We are hiring our first interns to accelerate product validation and business development, while both founders will spend time in the US raising our pre-seed round. The funding helps cover operational costs during this critical phase and gives us the runway needed to convert early traction into a scalable, fundable company.
The first real signal came from a Swiss biotech consultancy that needed to deliver a harmonized multi-omics data package to a pharma partner under tight deadlines. Their team estimated six to eight weeks of manual work. Using Omics-OS, we delivered the same result in less than a month, and they paid for it.
That project confirmed something important for us: the biggest bottleneck isn’t data analysis itself, it’s finding, cleaning, and harmonizing data. After that, we stopped describing ourselves as an AI bioinformatics platform and started positioning Omics-OS as an agentic data access layer for biotech R&D.
Can you briefly describe your project and where it stood when you entered Venture Kick?
Omics-OS makes biological research data accessible, harmonized, and actionable for both scientists and AI agents. We think of it as an operating system for biology.
The platform combines an open-source multi-agent engine for bioinformatics workflows with a managed cloud workspace that enables reproducible analyses and partner-ready data packages without coding.
When we entered Venture Kick, we already had a production-grade platform and our first paying customer. What we lacked was a clear commercial focus, a repeatable sales process, and the resources to start building a team.
How has the direction of your product/service/product strategy changed since working with the Venture Kick Team?
Before Venture Kick, we were trying to sell the entire vision at once. The program pushed us to focus on a specific, urgent customer problem.
Instead of leading with the platform, we now focus on helping biotech teams quickly generate harmonized, auditable data packages when facing partnership, diligence, or research deadlines. That shift influenced our pricing, messaging, outreach, and product priorities. The vision remains the same, but the path to getting there is much clearer.
How will the Stage 2 funding help you advance your project concretely?
Stage 2 funding will support two priorities: growing the team and advancing our fundraising efforts.
We are hiring our first interns to accelerate product validation and business development, while both founders will spend time in the US raising our pre-seed round. The funding helps cover operational costs during this critical phase and gives us the runway needed to convert early traction into a scalable, fundable company.